Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Cumberland Pharmaceuticals › CEO received an award of 100K CPIX derivative securities Insider trades
Derivative units · @ $2.80
Why it stands out Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Mar 18, 2026
Reporting period Not applicable
Filed with the SEC Mar 20, 2026 CEO Grant / award
Context Classification grant award
Code A — grant or award
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001087294-26-000032
Filed / recorded
Mar 20, 2026, 9:19 PM UTC
Added to OQRO Oct 8, 2026, 2:17 AM UTC
Data quality Verified: identifiers matched exactly
Issuer CUMBERLAND PHARMACEUTICALS INC
Reporting person A J Kazimi
Relationship Director, Officer, 10% owner
Officer title Chairman and CEO
Security Options (right to buy)
Table Derivative (Table II)
Transaction date Mar 18, 2026
Acquired / disposed Acquired (A)
Shares owned after 568,000
Around the same time Insider filing
Traded Mar 18 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Mar 18 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Mar 18 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Mar 3, 2026 Company filing · Form 8-K · Results Reported its results What came next Apr 22, 2026 Company filing · Form 8-K · Material agreement, Reg FD Signed an important agreement, and shared information with investors (and 1 more item) May 5, 2026 Company filing · Form 8-K · Results Reported its results Jun 29, 2026 Company filing · Form 8-K · Material agreement, Agreement ended Completed buying or selling a business or assets, and changed a top executive or board member (and 3 more items) “Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.”